What is the efficacy of osimertinib/osimertinib in the treatment of advanced lung cancer?

Osimertinib is a targeted therapy for advanced non-small cell lung cancer (NSCLC). It is particularly suitable for patients with positive EGFR gene mutations, especially those who are resistant to other EGFR inhibitors. Through the analysis of clinical trial data, we can gain an in-depth understanding of the efficacy of osimertinib/osimertinib in the treatment of advanced lung cancer.

1. Efficacy of first-line treatment

Clinical Trial FLAURA It is a global, double-blind, randomized, multicenter, parallel group III phase trial evaluating osimertinib/osimertinibEfficacy compared with standard first-line therapy (first- or second-generation EGFR inhibitors) in patients with advanced NSCLC with EGFR-sensitizing mutations. The study results show that Osimertinib/Osimertinib has achieved significant clinical benefits in first-line treatment:

Progression-free survival time (PFS) is prolonged: Osimertinib/The median progression-free survival time of the osimertinib group is longer than that of standard first-line treatment The treatment group was significantly longer, 18.9 months and 10.2 months respectively (HR=0.46, 95% CI 0.37-0.57, p<0.0001).

Overall survival time (OS) improved: Osimertinib/OsimertinibThe median overall survival time of the treatment group was slightly longer than that of the standard first-line treatment group, but the difference was not statistically significant (HR=0.80, 95% CI 0.64-1.00).

The objective response rate (ORR) was improved:Osiimertinib/The objective response rate in the osimertinib group was 80% (95% CI 76%-84%), compared with 76% in the standard first-line treatment group (95% CI 72%-80%).

2. Efficacy of drug resistance treatment

For EGFR T790MpositiveNSCLC patients, Osimertinib/Osimertinib showed a significant therapeutic effect on drug resistance. AURA3is a randomized, multicenter, open-label phase III trial comparing osimertinib/osimertinib with chemotherapy in EGFR Efficacy in patients with T790Mpositive advanced stageNSCLC. The results show:

Progression-free survival time (PFS) was prolonged: Osimertinib/The median progression-free survival time was significantly longer in the osimertinib group In the chemotherapy group, they were 10.1 months and 4.4 months respectively (HR=0.30, 95% CI 0.23-0.41, p<0.0001).

The objective response rate (ORR) was significantly improved: Osimertinib/The objective response rate in the osimertinib group was 71% (95% CI 65%-77%), while the chemotherapy group was 31% (95% CI 24%-40%).

3. Therapeutic efficacy of brain metastasis

Brain metastasis is a common clinical problem in patients with advanced NSCLC, and Osimertinib/Osimertinib also shows good efficacy in the treatment of brain metastasis. BLOOMis an open-label Phase II clinical trial evaluating osimertinib/osimertinibin the treatment of brain metastases in patients with advanced NSCLC whose EGFR gene mutation is positive. The results show:

Remarkable efficacy in brain metastasis:Osimertinib/Osimertinib has shown good efficacy in the treatment of brain metastasis. In the study, the brain metastasis lesions of some patients were significantly reduced or completely disappeared.

In summary, Osimertinib/Osimertinib, as a targeted therapy drug, has shown significant efficacy in the treatment of advanced lung cancer. It not only prolonged PFS in first-line treatment, but also showed good efficacy in drug-resistant treatment and brain metastasis treatment. However, patients still need to be closely monitored during treatment and deal with possible adverse reactions in a timely manner to ensure the safety and effectiveness of the treatment.